Humoral response to two doses of BNT162b2 vaccination in people with HIV

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Humoral response to two doses of BNT162b2 vaccination in people with HIV. / Heftdal, Line Dam; Knudsen, Andreas Dehlbæk; Hamm, Sebastian Rask; Hansen, Cecilie Bo; Møller, Dina Leth; Pries-Heje, Mia; Fogh, Kamille; Hasselbalch, Rasmus Bo; Jarlhelt, Ida; Pérez-Alós, Laura; Hilsted, Linda Maria; Ostrowski, Sisse Rye; Gerstoft, Jan; Grønbæk, Kirsten; Bundgaard, Henning; Iversen, Kasper; Garred, Peter; Nielsen, Susanne Dam.

In: Journal of Internal Medicine, Vol. 291, No. 4, 2022, p. 513-518.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Heftdal, LD, Knudsen, AD, Hamm, SR, Hansen, CB, Møller, DL, Pries-Heje, M, Fogh, K, Hasselbalch, RB, Jarlhelt, I, Pérez-Alós, L, Hilsted, LM, Ostrowski, SR, Gerstoft, J, Grønbæk, K, Bundgaard, H, Iversen, K, Garred, P & Nielsen, SD 2022, 'Humoral response to two doses of BNT162b2 vaccination in people with HIV', Journal of Internal Medicine, vol. 291, no. 4, pp. 513-518. https://doi.org/10.1111/joim.13419

APA

Heftdal, L. D., Knudsen, A. D., Hamm, S. R., Hansen, C. B., Møller, D. L., Pries-Heje, M., Fogh, K., Hasselbalch, R. B., Jarlhelt, I., Pérez-Alós, L., Hilsted, L. M., Ostrowski, S. R., Gerstoft, J., Grønbæk, K., Bundgaard, H., Iversen, K., Garred, P., & Nielsen, S. D. (2022). Humoral response to two doses of BNT162b2 vaccination in people with HIV. Journal of Internal Medicine, 291(4), 513-518. https://doi.org/10.1111/joim.13419

Vancouver

Heftdal LD, Knudsen AD, Hamm SR, Hansen CB, Møller DL, Pries-Heje M et al. Humoral response to two doses of BNT162b2 vaccination in people with HIV. Journal of Internal Medicine. 2022;291(4):513-518. https://doi.org/10.1111/joim.13419

Author

Heftdal, Line Dam ; Knudsen, Andreas Dehlbæk ; Hamm, Sebastian Rask ; Hansen, Cecilie Bo ; Møller, Dina Leth ; Pries-Heje, Mia ; Fogh, Kamille ; Hasselbalch, Rasmus Bo ; Jarlhelt, Ida ; Pérez-Alós, Laura ; Hilsted, Linda Maria ; Ostrowski, Sisse Rye ; Gerstoft, Jan ; Grønbæk, Kirsten ; Bundgaard, Henning ; Iversen, Kasper ; Garred, Peter ; Nielsen, Susanne Dam. / Humoral response to two doses of BNT162b2 vaccination in people with HIV. In: Journal of Internal Medicine. 2022 ; Vol. 291, No. 4. pp. 513-518.

Bibtex

@article{20879e9c79674c3f809038e3326115e5,

title = "Humoral response to two doses of BNT162b2 vaccination in people with HIV",

abstract = "Background: People with HIV (PWH) are at increased risk of severe COVID-19. We aimed to determine humoral responses in PWH and controls who received two doses of BNT162b2. Methods: In 269 PWH and 538 age-matched controls, we measured IgG and neutralizing antibodies specific for the receptor-binding domain of SARS-CoV-2 at baseline, 3 weeks and 2 months after the first dose of BNT162b2. Results: IgG antibodies increased from baseline to 3 weeks and from 3 weeks to 2 months in both groups, but the concentrations of IgG antibodies were lower in PWH than that in controls at 3 weeks and 2 months (p = 0.025 and <0.001), respectively. The IgG titres in PWH with a humoral response at 2 months were 77.9% (95% confidence interval [62.5%–97.0%], age- and sex-adjusted p = 0.027) of controls. Conclusions: Reduced IgG antibody response to vaccination with BNT162b2 was found in PWH, and thus increased awareness of breakthrough infections in PWH is needed.",

keywords = "antibody response, BNT162b2, HIV, SARS-CoV-2, vaccine",

author = "Heftdal, {Line Dam} and Knudsen, {Andreas Dehlb{\ae}k} and Hamm, {Sebastian Rask} and Hansen, {Cecilie Bo} and M{\o}ller, {Dina Leth} and Mia Pries-Heje and Kamille Fogh and Hasselbalch, {Rasmus Bo} and Ida Jarlhelt and Laura P{\'e}rez-Al{\'o}s and Hilsted, {Linda Maria} and Ostrowski, {Sisse Rye} and Jan Gerstoft and Kirsten Gr{\o}nb{\ae}k and Henning Bundgaard and Kasper Iversen and Peter Garred and Nielsen, {Susanne Dam}",

note = "Publisher Copyright: {\textcopyright} 2021 The Association for the Publication of the Journal of Internal Medicine",

year = "2022",

doi = "10.1111/joim.13419",

language = "English",

volume = "291",

pages = "513--518",

journal = "Journal of Internal Medicine",

issn = "0955-7873",

publisher = "Wiley-Blackwell",

number = "4",

}

RIS

TY - JOUR

T1 - Humoral response to two doses of BNT162b2 vaccination in people with HIV

AU - Heftdal, Line Dam

AU - Knudsen, Andreas Dehlbæk

AU - Hamm, Sebastian Rask

AU - Hansen, Cecilie Bo

AU - Møller, Dina Leth

AU - Pries-Heje, Mia

AU - Fogh, Kamille

AU - Hasselbalch, Rasmus Bo

AU - Jarlhelt, Ida

AU - Pérez-Alós, Laura

AU - Hilsted, Linda Maria

AU - Ostrowski, Sisse Rye

AU - Gerstoft, Jan

AU - Grønbæk, Kirsten

AU - Bundgaard, Henning

AU - Iversen, Kasper

AU - Garred, Peter

AU - Nielsen, Susanne Dam

PY - 2022

Y1 - 2022

N2 - Background: People with HIV (PWH) are at increased risk of severe COVID-19. We aimed to determine humoral responses in PWH and controls who received two doses of BNT162b2. Methods: In 269 PWH and 538 age-matched controls, we measured IgG and neutralizing antibodies specific for the receptor-binding domain of SARS-CoV-2 at baseline, 3 weeks and 2 months after the first dose of BNT162b2. Results: IgG antibodies increased from baseline to 3 weeks and from 3 weeks to 2 months in both groups, but the concentrations of IgG antibodies were lower in PWH than that in controls at 3 weeks and 2 months (p = 0.025 and <0.001), respectively. The IgG titres in PWH with a humoral response at 2 months were 77.9% (95% confidence interval [62.5%–97.0%], age- and sex-adjusted p = 0.027) of controls. Conclusions: Reduced IgG antibody response to vaccination with BNT162b2 was found in PWH, and thus increased awareness of breakthrough infections in PWH is needed.

AB - Background: People with HIV (PWH) are at increased risk of severe COVID-19. We aimed to determine humoral responses in PWH and controls who received two doses of BNT162b2. Methods: In 269 PWH and 538 age-matched controls, we measured IgG and neutralizing antibodies specific for the receptor-binding domain of SARS-CoV-2 at baseline, 3 weeks and 2 months after the first dose of BNT162b2. Results: IgG antibodies increased from baseline to 3 weeks and from 3 weeks to 2 months in both groups, but the concentrations of IgG antibodies were lower in PWH than that in controls at 3 weeks and 2 months (p = 0.025 and <0.001), respectively. The IgG titres in PWH with a humoral response at 2 months were 77.9% (95% confidence interval [62.5%–97.0%], age- and sex-adjusted p = 0.027) of controls. Conclusions: Reduced IgG antibody response to vaccination with BNT162b2 was found in PWH, and thus increased awareness of breakthrough infections in PWH is needed.

KW - antibody response

KW - BNT162b2

KW - HIV

KW - SARS-CoV-2

KW - vaccine

U2 - 10.1111/joim.13419

DO - 10.1111/joim.13419

M3 - Journal article

C2 - 34841629

AN - SCOPUS:85121385903

VL - 291

SP - 513

EP - 518

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

SN - 0955-7873

IS - 4

ER -

ID: 288196331

Department of Clinical Medicine